Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events | Zendy

Kazuyo Iwamoto | Zendy; Yosuke Ishitsuka | Zendy; Ryota Tanaka | Zendy; Ikuo Sekine | Zendy; Manabu Fujimoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events

Author(s) -

Kazuyo Iwamoto,

Yosuke Ishitsuka,

Ryota Tanaka,

Ikuo Sekine,

Manabu Fujimoto

Publication year - 2017

Publication title -

european journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.48

H-Index - 71

eISSN - 1952-4013

pISSN - 1167-1122

DOI - 10.1684/ejd.2017.2973

Subject(s) - medicine , ipilimumab , nivolumab , pneumonitis , pembrolizumab , adverse effect , immune system , azathioprine , immunology , hepatitis , cytotoxic t cell , colitis , pancreatitis , immunotherapy , lung , disease , biochemistry , chemistry , in vitro

Enhancement of anti-tumour immunity has led to substantial progress in the treatment of melanoma. Two types of immune checkpoint inhibitors, ipilimumab, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and pembrolizumab and nivolumab, targeting programmed cell death-1 (PD-1), are now available.Treatment with these agents can cause immune system-related adverse events (IRAEs) that manifest as pneumonitis, colitis, pancreatitis, hypothyroidism or hepatitis (i.e. hepatic IRAE) [1-3]. [...]

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research